Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 238

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1C
Chunk 238
---
,857,143  
     986  
     34,014  
     —  
     35,000 

    Net loss 
     —  
     —  
     —  
     (279,845) 
     (279,845)

    Balance — December 31, 2024 
     9,857,143  
    $986  
    $34,014  
    $(279,845) 
    $(244,845)

  (1) Includes an aggregate of up to 1,285,714 ordinary shares subject to surrender and forfeiture if the over-allotment option is not exercised in full by the underwriters (Note 5). In February 2025 the over-allotment option was exercised by the underwriters and these shares are no longer subject to forfeiture (Note 9).  (2) On November 6, 2024, the Sponsor surrendered and forfeited 12,503,968 ordinary shares to the Company for no consideration, following which the Sponsor holds 9,857,143 ordinary shares (the “Founder Shares”). All share and per share data has been retrospectively presented. 

The accompanying notes are an integral part
of the financial statements.

F-5

DRUGS MADE IN AMERICA ACQUISITION CORP.

STATEMENT OF CASH FLOWS

FOR THE PERIOD FROM MAY 23, 2024 (INCEPTION)
THROUGH DECEMBER 31, 2024

    Cash Flows from Operating Activities: 

    Net loss 
    $(279,845)
  
    Adjustments to reconcile net loss to net cash used in operating activities: 

    Operating costs paid through promissory note 
     30,300 
  
    Changes in operating assets and liabilities: 

    Accrued expenses 
     77,280 
  
    Net cash used in operating activities 
     (172,265)

    Cash Flows from Financing Activities: 

    Proceeds from issuance of Founder shares 
     35,000 
  
    Proceeds from promissory note - related party 
     1,802,648 
  
    Repayment of promissory note - related party 
     (1,300,433)
  
    Payment of offering costs 
     (363,599)
  
    Net cash provided by financing activities 
     173,616 

    Net Change